Australia - Inggris - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: sodium hydroxide; glycerol; metacresol; zinc oxide; phenol; dibasic sodium phosphate heptahydrate; protamine sulfate; hydrochloric acid; water for injections - this product accepted for registration as 'currently supplied' at the time of commencement of the act. humulin is indicated for the treatment of insulin-dependent diabetic patients.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

eli lilly and company - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - rezvoglar™ is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. limitations of use rezvoglar is not recommended for the treatment of diabetic ketoacidosis. rezvoglar is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] . - in patients with hypersensitivity to insulin glargine products or any of the excipients in rezvoglar [see warnings and precautions (5.5)] . risk summary published studies with use of insulin glargine products during pregnancy have not reported a clear association with insulin glargine products and adverse developmental outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dosage of 0.2 units/kg/day. overall, the effects of insulin glargine did not generally differ from those observed with regular human insulin (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the estimated background risk of major birth defects is 6% to 10% in women with pregestational diabetes with a peri-conceptional hba1c >7 and has been reported to be as high as 20% to 25% in women with a peri-conceptional hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. clinical considerations disease-associated maternal and/or embryo-fetal risk hypoglycemia and hyperglycemia occur more frequently during pregnancy in patients with pre-gestational diabetes. poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity. data human data published data do not report a clear association with insulin glargine products and major birth defects, miscarriage, or adverse maternal or fetal outcomes when insulin glargine is used during pregnancy. however, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and some lacking comparator groups. animal data subcutaneous reproduction and teratology studies have been performed with insulin glargine and regular human insulin in rats and himalayan rabbits. insulin glargine was given to female rats before mating, during mating, and throughout pregnancy at doses up to 0.36 mg/kg/day, which is approximately 50 times the recommended human subcutaneous starting dosage of 0.2 units/kg/day (0.007 mg/kg/day), on a mg/kg basis. in rabbits, doses of 0.072 mg/kg/day, which is approximately 10 times the recommended human subcutaneous starting dosage of 0.2 units/kg/day on a mg/kg basis, were administered during organogenesis. the effects of insulin glargine did not generally differ from those observed with regular human insulin in rats or rabbits. however, in rabbits, five fetuses from two litters of the high-dose group exhibited dilation of the cerebral ventricles. fertility and early embryonic development appeared normal. risk summary there are either no or only limited data on the presence of insulin glargine products in human milk, the effects on the breastfed infant, or the effects on milk production. endogenous insulin is present in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for rezvoglar and any potential adverse effects on the breastfed child from rezvoglar or from the underlying maternal condition. the safety and effectiveness of insulin glargine products to improve glycemic control in pediatric patients with diabetes mellitus have been established. use of insulin glargine for this indication is supported by evidence from an adequate and well-controlled study (study d) in 174 insulin glargine-treated pediatric patients aged 6 to 15 years with type 1 diabetes mellitus, and from adequate and well-controlled studies of insulin glargine in adults with diabetes mellitus [see clinical pharmacology (12.3), clinical studies (14.2)] . in the pediatric clinical study, pediatric patients with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia compared to the adults in studies with type 1 diabetes [see adverse reactions (6.1)] . of the total number of subjects in controlled clinical studies of patients with type 1 and type 2 diabetes who were treated with insulin glargine, 15% (n=316) were ≥65 years of age and 2% (n=42) were ≥75 years of age. no overall differences in safety or effectiveness of insulin glargine have been observed between patients 65 years of age and older and younger adult patients. nevertheless, caution should be exercised when rezvoglar is administered to geriatric patients. in geriatric patients with diabetes, the initial dosing, dosage increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions. hypoglycemia may be difficult to recognize in geriatric patients. the effect of kidney impairment on the pharmacokinetics of insulin glargine products has not been studied. some studies with human insulin have shown increased circulating levels of insulin in patients with kidney failure. frequent glucose monitoring and dosage adjustment may be necessary for rezvoglar in patients with kidney impairment [see warnings and precautions (5.3)] . the effect of hepatic impairment on the pharmacokinetics of insulin glargine products has not been studied. frequent glucose monitoring and dosage adjustment may be necessary for rezvoglar in patients with hepatic impairment [see warnings and precautions (5.3)] . instructions for use rezvoglartm kwikpen® (rehz-voh-glahr) (insulin glargine-aglr) injection, for subcutaneous use 3 ml single-patient-use prefilled-pen: 100 units/ml (u-100) read these instructions for use before you start taking the rezvoglar kwikpen (“pen”) and each time you get a new rezvoglar kwikpen. there may be new information. this information does not take the place of talking to your healthcare provider about your medical condition or your treatment. do not share your rezvoglar kwikpen with other people, even if the needle has been changed. you may give other people a serious infection, or get a serious infection from them. people who are blind or have vision problems should not use rezvoglar kwikpen prefilled pen without help from a person trained to use rezvoglar kwikpen prefilled pen. rezvoglar kwikpen is a disposable prefilled pen used to inject rezvoglar. each rezvoglar kwikpen has 300 units of insulin which can be used for multiple injections. you can select doses from 1 to 80 units in steps of 1 unit. the pen plunger moves with each dose, but you may not notice that it moves. the plunger will only move to the end of the cartridge when 300 units of rezvoglar have been given. important information you need to know before injecting rezvoglar - do not use your pen if it is damaged or if you are not sure that it is working properly. - do not use a syringe to remove rezvoglar from your pen. - do not reuse needles. if you do, you might get the wrong dose of rezvoglar and/or increase the chance of getting an infection. - always perform a safety test (prime the rezvoglar kwikpen) (see step 3 ). - always carry a spare pen and spare needles in case of loss or damage. - change (rotate) your injection sites within the area you choose for each dose (see “places to inject ”). learn to inject - talk with your healthcare provider about how to inject before using your pen. - ask for help if you have problems handling the pen, for example if you have problems with your sight. - read all these instructions before using your pen. if you do not follow all these instructions, you may get too much or too little insulin. need help? if you have any questions about your pen or about diabetes, ask your healthcare provider, or go to www.rezvoglar.com or call eli lilly and company at 1-800-545-5979. extra items you will need - a new sterile pen needle (see step 2 ). - an alcohol swab. - a puncture-resistant container for used needles and pens (see "throwing your pen away" ). places to inject - inject your insulin exactly as your healthcare provider has shown you. - inject your insulin under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen). - change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. - do not inject where the skin has pits, is thickened, or has lumps. - do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin. - do not try to change your dose while injecting. get to know your pen step 1: check your pen take a new pen out of the refrigerator at least 1 hour before you inject. cold insulin is more painful to inject. 1a check the name and expiration date on the label of your pen. the rezvoglar kwikpen is light grey with a light grey dose knob that has a green ring on the end. the label on the pen is light grey with green color bars. - make sure you have the correct insulin. - do not use your pen after the expiration date. 1b pull off the pen cap. 1c check that the insulin is clear. - do not use the pen if the insulin looks cloudy, colored or contains particles. 1d wipe the rubber seal with an alcohol swab. if you have other injector pens: - making sure you have the correct medicine is especially important if you have other injector pens. step 2: attach a new needle - do not re-use needles. always use a new sterile needle for each injection. this helps stop blocked needles, contamination, and infection. only use needles that are compatible with rezvoglar kwikpen. becton, dickinson and company (bd) pen needles are recommended. these are sold separately. contact your healthcare provider for further information. 2a take a new needle and peel off the paper tab. 2b keep the needle straight and screw it onto the pen until fixed. do not over-tighten. 2c pull off the outer needle shield. keep this for later. 2d pull off the inner needle shield and throw away. handling needles - take care when handling needles to prevent needle-stick injury and cross-infection. step 3: do a safety test (prime your rezvoglar kwikpen) always do a safety test (prime) before each injection to: - check your pen and the needle to make sure they are working properly. - make sure that you get the correct rezvoglar dose. 3a select 2 units by turning the dose knob until the dose indicator is at the 2 mark. 3b press the dose knob all the way in. when insulin comes out of the needle tip, your pen is working correctly: if no insulin appears: - you may need to repeat this step up to 4 times before seeing insulin. - if no insulin comes out after the fourth time, the needle may be blocked. if this happens: change the needle (see step 6 and step 2 ), then repeat the safety test (prime) (step 3 ). - change the needle (see step 6 and step 2 ), - then repeat the safety test (prime) (step 3 ). - do not use your pen if there is still no insulin coming out of the needle tip. use a new pen. - do not use a syringe to remove insulin from your pen. if you see air bubbles: - you may see air bubbles in the insulin. this is normal, they will not harm you. step 4: select the dose do not select a dose or press the dose knob without a needle attached. this may damage your pen. 4a make sure a needle is attached and the dose is set to "0". 4b turn the dose knob until the dose indicator lines up with your dose. - if you turn past your dose, you can turn back down. - the dose knob clicks as you turn it. do not dial your dose by counting the clicks because you may dial the wrong dose. - if there are not enough units left in your pen for your dose, the dose indicator will stop at the number of units left. - if you cannot select your full prescribed dose, use a new pen or inject the remaining units and use a new pen to complete your dose. how to read the dose window even numbers are shown in line with dose indicator. (example: 12 units shown in the dose window) odd numbers, after the number 1, are shown as a line between even numbers. (example: 25 units shown in the dose window) units of rezvoglar in your pen: - your pen contains a total of 300 units of rezvoglar. you can select doses from 1 to 80 in steps of 1 unit. each pen contains more than 1 dose. - you can see roughly how many units of insulin are left by looking at where the plunger is on the insulin scale. step 5: injecting your rezvoglar dose if you find it hard to press the dose knob in, do not force it as this may break your pen. see the section below for help. 5a choose a place to inject as shown in the picture above. 5b push the needle into the skin as shown by your healthcare provider. do not touch the dose knob yet. 5c place your thumb on the dose knob. then press all the way in and hold. 5d keep the dose knob held in and when you see "0" in the dose window, slowly count to 5. - this will make sure you get your full dose. - do not try to inject your insulin by turning the dose knob. you will not receive your insulin by turning the dose knob. 5e after holding and slowly counting to 5, release the dose knob. then remove the needle from your skin. - if you do not see “0” in the dose window, you did not receive your full dose. do not redial. insert the needle into your skin and finish your injection. - if you still do not think you received the full amount you dialed for your injection, do not start over or repeat the injection. monitor your blood glucose and call your healthcare provider for further instructions. if you find it hard to press the dose knob in: - change the needle (see step 6 and step 2 ) then do a safety test (prime the pen) (see step 3 ). - if you still find it hard to press in, get a new pen. - do not use a syringe to remove insulin from your pen. step 6: remove the needle - take care when handling needles to prevent needle-stick injury and cross-infection. - do not put the inner needle shield back on. 6a leave the outer needle shield on a flat surface. using one hand, scoop the outer needle shield straight onto the needle. when the tip is covered, lift the needle and pen. then push firmly on. 6b grip and squeeze the widest part of the outer needle shield. turn your pen several times with your other hand to remove the needle. - try again if the needle does not come off the first time. 6c throw away the used needle in a puncture-resistant container (see "throwing your pen away" at the end of this instructions for use). 6d put your pen cap back on - do not put the pen back in the refrigerator. storing the rezvoglar kwikpen before first use - keep new pens in the refrigerator between 36°f to 46°f (2°c to 8°c). - do not freeze. do not use rezvoglar if it has been frozen. - unused pens may be used until the expiration date printed on the label, if the pen has been kept in the refrigerator. after first use - keep your pen at room temperature below 86°f (30°c) . - keep your pen away from heat or light. - store your pen with the pen cap on. - do not put your pen back in the refrigerator. - do not store your pen with the needle attached. - keep out of the reach of children. - only use your pen for up to 28 days after its first use. throw away the rezvoglar kwikpen you are using after 28 days, even if it still has insulin left in it. caring for your rezvoglar kwikpen handle your pen with care - do not drop your pen or knock it against hard surfaces. - if you think that your pen may be damaged, do not try to fix it. use a new one. protect your pen from dust and dirt - you can clean the outside of your pen by wiping it with a damp cloth (water only). do not soak, wash or lubricate your pen. this may damage it. throwing your pen away - the used rezvoglar kwikpen may be thrown away in your household trash after you have removed the needle. - put the used needle in an fda-cleared sharps disposal container right away after use. do not throw away (dispose of) the used needles in your household trash. - if you do not have a fda-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. - made of a heavy-duty plastic, - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, - upright and stable during use, - leak-resistant, and - properly labeled to warn of hazardous waste inside the container. - when your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. there may be state or local laws about how you should throw away used needles and syringes. for more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the fda’s website at: http://www.fda.gov/safesharpsdisposal. - do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. do not recycle your used sharps disposal container. this instructions for use has been approved by the u.s. food and drug administration. manufactured by: eli lilly and company indianapolis, in 46285, usa us license number 1891 copyright © 2021, 2022, eli lilly and company. all rights reserved. rezvoglartm and rezvoglartm kwikpen® are trademarks of eli lilly and company. instructions for use revised: nov 2022 rezkp-0002-ifu-20221116

Uni Eropa - Inggris - EMA (European Medicines Agency)

eli lilly and company limited  - meloxicam - musculo-skeletal system - dogs - alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.

Uni Eropa - Inggris - EMA (European Medicines Agency)

eli lilly and company limited - spinosad, milbemycin oxime - antiparasitic products, insecticides and repellents, endectocides - dogs - for the treatment and prevention of flea (ctenocephalides felis) infestations in dogs where one or more of the following indications are required concurrently: prevention of heartworm disease (l3, l4 dirofilaria immitis);prevention of angiostrongylosis by reducing the level of infection with immature adult (l5) angiostrongylus vasorum;treatment of gastrointestinal nematode infections caused by hookworm (l4, immature adult, l5) and adult ancylostoma caninum), roundworms (immature adult l5, and adult toxocara canis and adult toxascaris leonina) and whipworm (adult trichuris vulpis). 

Uni Eropa - Inggris - EMA (European Medicines Agency)

eli lilly and company (ireland) limited - ixekizumab - psoriasis - immunosuppressants - plaque psoriasistaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritistaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (dmard) therapies.

Israel - Inggris - Ministry of Health

eli lilly israel ltd, israel - baricitinib - film coated tablets - baricitinib 4 mg - baricitinib - rheumatoid arthritisolumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. olumiant may be used as monotherapy or in combination with methotrexate.atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.alopecia areataolumiant is indicated for the treatment of severe alopecia areata in adult patients.

Israel - Inggris - Ministry of Health

eli lilly israel ltd, israel - galcanezumab - solution for injection - galcanezumab 120 mg / 1 ml - galcanezumab - emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Israel - Inggris - Ministry of Health

eli lilly israel ltd, israel - ramucirumab - concentrate for solution for infusion - ramucirumab 10 mg/ml - ramucirumab - gastric cancercyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.colorectal cancercyramza, in combination with folfiri (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.non-small cell lung cancercyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung adenocarcinoma with activating epidermal growth factor receptor (egfr) mutations.cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.hepatocellular carcinomacyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (afp) of ≥ 400 ng/ml and who have been previously treated with sorafenib.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - nortriptyline hydrochloride 11.4mg equivalent to to 10 mg nortriptyline base;   - tablet - 10 mg - active: nortriptyline hydrochloride 11.4mg equivalent to to 10 mg nortriptyline base   excipient: calcium phosphate glycerol hypromellose lactose monohydrate magnesium stearate starch

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - nortriptyline hydrochloride 28.5mg equivalent to 25 mg nortriptyline base;   - tablet - 25 mg - active: nortriptyline hydrochloride 28.5mg equivalent to 25 mg nortriptyline base   excipient: calcium phosphate glycerol hypromellose lactose monohydrate magnesium stearate starch sunset yellow fcf